Press release Communiqué de presse
Press release Communiqué de presse
June 2, 2014 2 June, 2014
Sernova Provides Corporate Update and Results of 2014 Annual General Meeting
June 3rd, 2014, 6:00 a.m. EST
LONDON, ONTARIO--(Marketwire – June 3rd, 2014) - Sernova Corp. (TSX-V: SVA), a clinical stage company developing medical technologies for the long-term treatment of chronic debilitating metabolic diseases including diabetes and haemophilia today provides a corporate update and results of its 2014 Annual General Meeting (AGM).
Dr. Philip Toleikis, CEO of Sernova, commented “This is an exciting time for Sernova. We are continuing our Cell Pouch(TM) clinical trial with Dr. James Shapiro of the University of Alberta for the treatment of Type I diabetes, and have reached agreement with Medicyte Gmbh for the initiation of proof of concept studies of our Cell Pouch (TM) with Factor VIII producing cells to treat haemophilia. We have also increased our board membership and brought on several seasoned business development members to assist the Sernova team as we further develop the Company.”
Dr. Toleikis further stated, “Along with our current programs, we are seeking to develop additional clinical applications for the Cell Pouch(TM), and our new business development team is in discussions with other potential corporate and academic partners to further expand the depth of our technologies. These advances should continue to build shareholder value and benefit patients with chronic diseases.”
Selected 2013 and 2014 Corporate Developments Following are highlights of significant developments at Sernova during the past year: • Released positive interim results from our human clinical trial of the Cell Pouch(TM) with insulin producing islets for the treatment of Type I diabetes, demonstrating biocompatibility and safety for up to 6 months, as well as proof of 30 day islet survival within the Cell Pouch™ following islet transplant. The clinical trial is ongoing. • Established an agreement with Medicyte GmbH and initiated preclinical studies to jointly evaluate the use of Medicyte’s upcyte® cells in Sernova’s Cell Pouch(TM) to treat patients with haemophilia A. • Received the first patent allowance for Methods and Devices for Cellular Transplantation from the Australian Patent Office. • Continued evaluation of our Sertolin(TM) local immune protection technology within the Cell Pouch(TM) for treatment of chronic diseases following receipt of a contribution agreement for up to $254,300 from the National Research Council of Canada for continued research and development. • Closed non-brokered private placement of $2 million, comprising 10 million units at a price of $0.20. Each unit consisted of 1 common share and 1 common share purchase warrant exercisable at $0.35 for the first 24 months and $0.40 for the subsequent 12 months. • Appointed biopharma entrepreneur and investor Frank Holler to the Board of Directors. • Established a world class business development team of Kevin Egan and Nick Borrelly to establish corporate partners for Sernova’s programs and to expand Sernova’s proprietary technologies through academic and corporate partnerships. • Appointed Mr. David Garland CPA CA, CPA CMA, MAcc, BA(Hon) as interim CFO to replace Ms. Cathy Steiner, who has moved on to pursue other business interests. Mr. Garland has extensive public company experience and has been CFO of Highcourt Partners, LTD, Mash Media Solutions, Inc., and Wi-LAN V-chip Corp and has worked as VP Finance and/or Controller at Pathways to Education, Certicom Corp, and Delano Technology Corporation. 2014 AGM Appointments • Dr. George Adams (Chair), Frank Holler, Jeffrey Bacha, James Parsons, Bruce Weber and Dr. Philip Toleikis, were elected as the directors of the Company to hold office until the next annual general meeting of shareholders. • Davidson & Company, Chartered Accountants, was appointed auditor of the Company until the close of the next annual general meeting of shareholders, at a remuneration to be fixed by the Directors.
About Sernova Sernova Corp is a clinical stage regenerative medicine company developing medical technologies for the treatment of chronic debilitating metabolic diseases such as diabetes, blood disorders including haemophilia and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. Sernova is developing the Cell Pouch(TM), an implantable medical device for therapeutic cells (donor, xenogeneic or stem cells) which then release proteins and/or hormones as required. The therapeutic cells are protected from immune attack by Sernova’s proprietary technologies.
For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 email@example.com firstname.lastname@example.org www.sernova.com
Ray Matthews & Associates Ray Matthews Suite 601-128 West Cordova Street, Vancouver, BC V6B 0E6 Tel: (604) 818-7778 www.raymatthews.ca
Forward Looking Information This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of Sernova’s management on the date such statements were made. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.